Plegridy
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Biogen has developed Plegridy as a follow-on product to its leading MS therapy Avonex. Plegridy can be dosed fortnightly, compared to Avonex’s once-weekly dosing regimen. It is proposed that by attaching a polyethylene glycol link, the active interferon beta-1a component is protected from degradation, extending the lifetime of the drug and thus reducing the frequency of injections, providing a more effective and convenient dosing option.
Plegridy was first approved by the European Medicines Agency in July 2014, with the US Food and Drug Administration later approving Plegridy in August 2014, following a three-month extension to the standard review period.
TABLE OF CONTENTS
4 Product Profiles
4 Plegridy : Multiple sclerosis (MS)
LIST OF FIGURES
8 Figure 31: Rebif for multiple sclerosis – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary for Plegridy in multiple sclerosis
10 Figure 38: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Plegridy drug profile
6 Table 2: Plegridy pivotal trial data in multiple sclerosis
11 Table 3: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Aubagio 
Sign up to the